Use of smoking cessation pharmacotherapies during pregnancy is not associated with increased risk of adverse pregnancy outcomes: A population-based cohort study

BMC Medicine

Volumn 18, Issue 1, 2020, Pages

  Tran, Duong Thuy ^a   Preen, David B ^b   Einarsdottir, Kristjana ^c   Kemp Casey, Anna ^d   Randall, Deborah ^e   Jorm, Louisa R ^a   Choi, Stephanie K Y ^a   Havard, Alys ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF ICELAND   (Iceland)

^d UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Adverse outcomes; Australia; Birth defects; Bupropion; Nicotine replacement therapy; Pregnancy; Smoking cessation pharmacotherapy; Smoking in pregnancy; Varenicline

Indexed keywords

AMFEBUTAMONE; VARENICLINE; NICOTINIC AGENT;

ADVERSE OUTCOME; APGAR SCORE; ARTICLE; ATTITUDE TO PREGNANCY; CLINICAL DECISION MAKING; COHORT ANALYSIS; COMORBIDITY; CONGENITAL MALFORMATION; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HIGH RISK BEHAVIOR; HIGH RISK INFANT; HOSPITAL ADMISSION; HUMAN; MATERNAL EXPOSURE; MORBIDITY; NICOTINE REPLACEMENT THERAPY; POPULATION RESEARCH; PREGNANCY OUTCOME; PREMATURE LABOR; PREMATURITY; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SMALL FOR DATE INFANT; SMOKING CESSATION; SMOKING HABIT; TREND STUDY; ADULT; PREGNANCY; PROCEDURES; RISK FACTOR;

ADULT; COHORT STUDIES; FEMALE; HUMANS; NICOTINIC AGONISTS; PREGNANCY; RISK FACTORS; SMOKING CESSATION;

EID: 85078965557     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-019-1472-9     Document Type: Article

References (60)

1. Coleman T, Chamberlain C, Davey MA, Cooper SE, Leonardi-Bee J. Pharmacological interventions for promoting smoking cessation during pregnancy. Cochrane Database Syst Rev. 2015;12.
2. The Royal Australian College of General Practitioners. Supporting smoking cessation: a guide for health professionals. Melbourne: The Royal Australian College of General Practitioners; 2014.
3. Schneider S, Huy C, Schutz J, Diehl K. Smoking cessation during pregnancy: a systematic literature review. Drug Alcohol Rev. 2010;29(1):81-90.
4. Tran D, Roberts C, Jorm L, Seeho S, Havard A. Change in smoking status during two consecutive pregnancies: a population-based cohort study. BJOG. 2014;121(13):1611-20.
5. Koren G. Nicotine-replacement therapy in pregnancy-the end of the road? Ther Drug Monit. 2012;34(5):487-8.
6. Haddad A, Davis AM. Tobacco smoking cessation in adults and pregnant women: behavioral and pharmacotherapy interventions. JAMA. 2016;315(18):2011-2.
7. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;5:CD009329.
8. Turner E, Jones M, Vaz LR, Coleman T. Systematic review and meta-analysis to assess the safety of bupropion and varenicline in pregnancy. Nicotine Tob Res. 2019;21(8):1001-10.
9. The American College of Obstetricians and Gynecologists. Committee opinion no. 721: smoking cessation during pregnancy. Obstet Gynecol. 2017;130(\):e200.
10. World Health Organization. WHO recommendations for the prevention and management of tobacco use and second-hand smoke exposure in pregnancy. Geneva: World Health Organization; 2013.
11. Kaplan YC, Olgac Dündar N, Kasap B, Karadas B. Pregnancy outcome after varenicline exposure in the first trimester. Case Rep Obstet Gynecol. 2014;2014:263981.
12. Harrison-Woolrych M, Paterson H, Tan M. Exposure to the smoking cessation medicine varenicline during pregnancy: a prospective nationwide cohort study. Pharmacoepidemiol Drug Saf. 2013;22(10):1086-92.
13. Richardson JL, Stephens S, Yates LM, Diav-Citrin O, Arnon J, Beghin D, et al. Pregnancy outcomes after maternal varenicline use; analysis of surveillance data collected by the European Network of Teratology Information Services. Reprod Toxicol. 2017;67:26-34.
14. Stotts AL, Northrup TF, Cinciripini PM, Minnix JA, Blalock JA, Mullen PD, et al. Randomized, controlled pilot trial of bupropion for pregnant smokers: challenges and future directions. Am J Perinatol. 2015;32(4):351-6.
15. Nanovskaya TN, Oncken C, Fokina VM, Feinn RS, Clark SM, West H, et al. Bupropion sustained release for pregnant smokers: a randomized, placebo-controlled trial. Am J Obstet Gynecol. 2017;216(4):420.e1-9.
16. Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A, et al. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol. 2005;192(3):932-6.
17. Bérard A, Zhao J-P, Sheehy O. Success of smoking cessation interventions during pregnancy. Am J Obstet Gynecol. 2016;215(5):611.e1-8.
18. Berlin I, Grangé G, Jacob N, Tanguy M-L. Nicotine patches in pregnant smokers: randomised, placebo controlled, multicentre trial of efficacy. BMJ. 2014;348:g1622.
19. Lassen TH, Madsen M, Skovgaard LT, Strandberg-Larsen K, Olsen J, Andersen AM. Maternal use of nicotine replacement therapy during pregnancy and offspring birthweight: a study within the Danish National Birth Cohort. Paediatr Perinat Epidemiol. 2010;24(3):272-81.
20. Strandberg-Larsen K, Tinggaard M, Nybo Andersen AM, Olsen J, Gronbaek M. Use of nicotine replacement therapy during pregnancy and stillbirth: a cohort study. BJOG. 2008;115(11):1405-10.
21. Gaither KH, Brunner Huber LR, Thompson ME, Huet-Hudson YM. Does the use of nicotine replacement therapy during pregnancy affect pregnancy outcomes? Matern Child Health J. 2009;13(4):497-504.
22. Havard A, Jorm LR, Preen D, Daube M, Kemp A, Einarsdóttir K, et al. The Smoking MUMS (Maternal Use of Medications and Safety) Study: protocol for a population-based cohort study using linked administrative data. BMJ Open. 2013;3(9).
23. Roper L, Tran DT, Einarsdóttir K, Preen DB, Havard A. Algorithm for resolving discrepancies between claims for smoking cessation pharmacotherapies during pregnancy and smoking status in delivery records: the impact on estimates of utilisation. PLoS One. 2018;13(8):e0202999.
24. Tran DT, Havard A, Jorm LR. Data cleaning and management protocols for linked perinatal research data: a good practice example from the Smoking MUMS (Maternal Use of Medications and Safety) Study. BMC Med Res Methodol. 2017;17(1):97.
25. Tran DT, Roberts CL, Havard A, Jorm LR. Linking birth records to hospital admission records enhances the identification of women who smoke during pregnancy. Aust N Z J Public Health. 2014;38(3):258-64.
26. National Centre for Classification in Health. The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM)-Fifth Edition-Tabular list of diseases and Alphabetic index of diseases. Sydney: National Centre for Classification in Health, Faculty of Health Sciences, The University of Sydney; 2008.
27. New South Wales Department of Health. Maternity - Towards Normal Birth in NSW. Maternity and Child Health Unit - Strategic Development Division 2010.
28. Hutchinson M. Western Australia's mothers and babies, 2012: 30th annual report of the Western Australian midwives notification system; 2015.
29. WHO Collaborating Centre for Drug Statistics Methodology. ATC alterations from 2005-2019. Geneva: World Health Organization; 2019. https://www.whocc.no/atc_ddd_alterations__cumulative/atc_alterations/?order_by=1. Accessed 7 July 2019
30. Dobbins TA, Sullivan EA, Roberts CL, Simpson JM. Australian national birthweight percentiles by sex and gestational age, 1998-2007. MJA. 2012;197(5):291-4.
31. Lain SJ, Algert CS, Nassar N, Bowen JR, Roberts CL. Incidence of severe adverse neonatal outcomes: use of a composite indicator in a population cohort. Matern Child Health J. 2012;16(3):600-8.
32. Roberts CL, Cameron CA, Bell JC, Algert CS, Morris JM. Measuring maternal morbidity in routinely collected health data: development and validation of a maternal morbidity outcome indicator. Med Care. 2008;46(8):786-94.
33. Conde-Agudelo A, Rosas-Bermudez A, Kafury-Goeta AC. Birth spacing and risk of adverse perinatal outcomes: a meta-analysis. JAMA. 2006;295(15):1809-23.
34. Appareddy S, Pryor J, Bailey B. Inter-pregnancy interval and adverse outcomes: evidence for an additional risk in health disparate populations. J Matern Fetal Neonatal Med. 2017;30(21):2640-4.
35. Australian Therapeutic Goods Administration. Reporting adverse events: Australian Department of Health; 2018. https://www.tga.gov.au/reporting-adverse-events#faq. Accessed 25 Oct 2019.
36. Australian Bureau of Statistics 2033.0.55.001. Census of population and housing: socio-economic indexes for areas (SEIFA), Australia 2006: Australian Bureau of Statistics; 2008. http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/2033.0.55.001Main+Features12006?OpenDocument. Accessed 5 Feb 2018.
37. Australian Bureau of Statistics. Australian Standard Geographic Classification Remoteness Structure: Commonwealth of Australia; 2010. http://www.abs.gov.au/websitedbs/D3310114.nsf/home/remoteness+structure. Accessed 15 Apr 2019.
38. Parsons LS. Performing a 1:N case-control match on propensity sore. Proceedings of the Twenty -Sixth Annual SAS Users Group International Conference; 2004.
39. Nguyen T-L, Collins GS, Spence J, Daurès J-P, Devereaux PJ, Landais P, et al. Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance. BMC Med Res Methodol. 2017;17(1):78.
40. Hartmann-Boyce J, Stead LF, Cahill K, Lancaster T. Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews. Addiction. 2014;109(9):1414-25.
41. McCowan LME, Dekker GA, Chan E, Stewart A, Chappell LC, Hunter M, et al. Spontaneous preterm birth and small for gestational age infants in women who stop smoking early in pregnancy: prospective cohort study. BMJ. 2009;338:b1081.
42. Soneji S, Beltrán-Sánchez H. Association of maternal cigarette smoking and smoking cessation with preterm birth. JAMA Netw Open. 2019;2(4):e192514-e.
43. Blatt K, Moore E, Chen A, Van Hook J, DeFranco EA. Association of reported trimester-specific smoking cessation with fetal growth restriction. Obstet Gynecol. 2015;125(6):1452-9.
44. Centre for Epidemiology and Evidence. Quality and coverage of the NSW Register of Congenital Conditions using Admitted Patient Data: a record linkage study. Sydney: NSW Ministry of Health; 2016. https://www.health.nsw.gov.au/hsnsw/Pages/rocc-apd-linkage-study.aspx. Accessed 4 Apr 2018
45. Centers for Disease Control and Prevention. Update on overall prevalence of major birth defects-Atlanta, Georgia, 1978-2005. MMWR Morb Mortal Wkly Rep. 2008;57(1):1-5.
46. European Surveillance of Congenital Anomalies. EUROCAT prevalence data tables. Cases and prevalence (per 10,000 births) of all congenital anomaly subgroups for all registries, from 2012-2016 2018. http://www.eurocat-network.eu/accessprevalencedata/prevalencetables. Accessed 9 Apr 2019.
47. Pfizer Laboratories. Chantix (full prescribing information) 2019. http://labeling.pfizer.com/ShowLabeling.aspx?id=557. Accessed 2 Apr 2019.
48. Scialli AR, Daston G, Chen C, Coder PS, Euling SY, Foreman J, et al. Rethinking developmental toxicity testing: evolution or revolution? Birth Defects Res. 2018;110(10):840-50.
49. Bracken MB. Why animal studies are often poor predictors of human reactions to exposure. J R Soc Med. 2009;102(3):120-2.
50. Fokina VM, West H, Oncken C, Clark S, Ahmed MS, Hankins G, et al. Bupropion therapy during pregnancy: concentrations of the drug and its major metabolites in umbilical cord plasma and amniotic fluid. Drug Alcohol Depend. 2017;171:e63.
51. Ross EJ, Graham DL, Money KM, Stanwood GD. Developmental consequences of fetal exposure to drugs: what we know and what we still must learn. Neuropsychopharmacology. 2015;40(1):61-87.
52. Dempsey D, Jacob P, Benowitz NL. Accelerated metabolism of nicotine and cotinine in pregnant smokers. J Pharmacol Exp Ther. 2002;301(2):594.
53. Jackson JW, Schmid I, Stuart EA. Propensity scores in pharmacoepidemiology: beyond the horizon. Curr Epidemiol Rep. 2017;4(4):271-80.
54. Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol. 2007;167(4):492-9.
55. Taylor L, Pym M, Bajuk B, Sutton L, Travis S, Banks C. Validation study NSW midwives data collection 1998. Sydney: NSW Health Department; 2000.
56. Downey F. Validation study of the Western Australian midwives notification system. 2005 data. Department of Health, Western Australia: Perth; 2007.
57. US Food and Drug Administration. FDA drug safety communication: FDA revises description of mental health side effects of the stop-smoking medicines Chantix (varenicline) and Zyban (bupropion) to reflect clinical trial findings 2016. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-revises-description-mental-health-side-effects-stop-smoking. Accessed 25 Oct 2019.
58. Davey ME, Hunt JM, Foster R, Couzos S, van der Sterren AE, Sarin J, et al. Tobacco control policies and activities in aboriginal community-controlled health services. Med J Aust. 2015;202(10):S63-6.
59. Greenhalgh EM, Scollo MM, Pearce M. 9.1 socio-economic position and disparities in tobacco exposure and use. In: Scollo MM, Winstanley MH, editors. Tobacco in Australia: facts and issues. Melbourne: Cancer Council Victoria; 2018.
60. Cancer Council New South Wales. NRT factsheet 2016. https://www.cancercouncil.com.au/wp-content/uploads/2016/09/16138_CA_CAN5084_NRTFactsheet_WEB.pdf. Accessed 25 Oct 2019.